GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Telomir Pharmaceuticals Inc (NAS:TELO) » Definitions » Debt-to-EBITDA

Telomir Pharmaceuticals (Telomir Pharmaceuticals) Debt-to-EBITDA : 0.00 (As of Mar. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Telomir Pharmaceuticals Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Telomir Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.00 Mil. Telomir Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.00 Mil. Telomir Pharmaceuticals's annualized EBITDA for the quarter that ended in Mar. 2024 was $-7.66 Mil. Telomir Pharmaceuticals's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 was 0.00.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Telomir Pharmaceuticals's Debt-to-EBITDA or its related term are showing as below:

TELO' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.01   Med: -0.01   Max: -0.01
Current: -0.01

During the past 3 years, the highest Debt-to-EBITDA Ratio of Telomir Pharmaceuticals was -0.01. The lowest was -0.01. And the median was -0.01.

TELO's Debt-to-EBITDA is ranked worse than
100% of 279 companies
in the Biotechnology industry
Industry Median: 1.43 vs TELO: -0.01

Telomir Pharmaceuticals Debt-to-EBITDA Historical Data

The historical data trend for Telomir Pharmaceuticals's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Telomir Pharmaceuticals Debt-to-EBITDA Chart

Telomir Pharmaceuticals Annual Data
Trend Dec21 Dec22 Dec23
Debt-to-EBITDA
- - -0.01

Telomir Pharmaceuticals Quarterly Data
Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only - -0.09 -0.35 - -

Competitive Comparison of Telomir Pharmaceuticals's Debt-to-EBITDA

For the Biotechnology subindustry, Telomir Pharmaceuticals's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Telomir Pharmaceuticals's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Telomir Pharmaceuticals's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Telomir Pharmaceuticals's Debt-to-EBITDA falls into.



Telomir Pharmaceuticals Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Telomir Pharmaceuticals's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.101 + 0) / -11.429
=-0.01

Telomir Pharmaceuticals's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 0) / -7.664
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Mar. 2024) EBITDA data.


Telomir Pharmaceuticals  (NAS:TELO) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Telomir Pharmaceuticals Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Telomir Pharmaceuticals's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Telomir Pharmaceuticals (Telomir Pharmaceuticals) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
Website
Telomir Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical company focused on the development and commercialization of TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic treatment for human stem cells.

Telomir Pharmaceuticals (Telomir Pharmaceuticals) Headlines